AR109859A1 - Inhibidor de bromodominio - Google Patents
Inhibidor de bromodominioInfo
- Publication number
- AR109859A1 AR109859A1 ARP170102935A ARP170102935A AR109859A1 AR 109859 A1 AR109859 A1 AR 109859A1 AR P170102935 A ARP170102935 A AR P170102935A AR P170102935 A ARP170102935 A AR P170102935A AR 109859 A1 AR109859 A1 AR 109859A1
- Authority
- AR
- Argentina
- Prior art keywords
- methylsulfonylphenyl
- cyclopropylmethoxy
- methylisoquinolin
- pharmaceutical composition
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410756P | 2016-10-20 | 2016-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109859A1 true AR109859A1 (es) | 2019-01-30 |
Family
ID=62019669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102935A AR109859A1 (es) | 2016-10-20 | 2017-10-20 | Inhibidor de bromodominio |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3528810A4 (zh) |
| JP (3) | JP7129973B2 (zh) |
| CN (1) | CN110099685A (zh) |
| AR (1) | AR109859A1 (zh) |
| AU (1) | AU2017345468B2 (zh) |
| TW (1) | TW201821062A (zh) |
| WO (1) | WO2018075796A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| MX2021000657A (es) * | 2018-07-23 | 2021-05-12 | Celgene Quanticel Res Inc | Proceso para la preparacion de inhibidor de bromodominio. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020071931A (ko) * | 2000-01-07 | 2002-09-13 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석 |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2015018521A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| EP3038612B1 (en) * | 2013-08-30 | 2020-07-29 | Icahn School of Medicine at Mount Sinai | Cyclic vinylogous amides as bromodomain inhibitors |
| FI3640241T3 (fi) * | 2013-10-18 | 2023-01-13 | Bromodomeeni-inhibiittorit | |
| CN105960239A (zh) | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
| TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
| CN105732624B (zh) * | 2016-01-28 | 2019-08-02 | 中国药科大学 | 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途 |
-
2017
- 2017-10-19 AU AU2017345468A patent/AU2017345468B2/en active Active
- 2017-10-19 WO PCT/US2017/057439 patent/WO2018075796A1/en unknown
- 2017-10-19 EP EP17862619.8A patent/EP3528810A4/en active Pending
- 2017-10-19 JP JP2019521064A patent/JP7129973B2/ja active Active
- 2017-10-19 CN CN201780076154.0A patent/CN110099685A/zh active Pending
- 2017-10-20 TW TW106136093A patent/TW201821062A/zh unknown
- 2017-10-20 AR ARP170102935A patent/AR109859A1/es unknown
-
2022
- 2022-04-14 JP JP2022066855A patent/JP2022095897A/ja active Pending
-
2024
- 2024-02-15 JP JP2024021416A patent/JP2024056905A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110099685A (zh) | 2019-08-06 |
| JP2019535671A (ja) | 2019-12-12 |
| AU2017345468B2 (en) | 2022-06-02 |
| WO2018075796A1 (en) | 2018-04-26 |
| TW201821062A (zh) | 2018-06-16 |
| JP2024056905A (ja) | 2024-04-23 |
| EP3528810A4 (en) | 2020-06-17 |
| EP3528810A1 (en) | 2019-08-28 |
| AU2017345468A1 (en) | 2019-06-06 |
| JP2022095897A (ja) | 2022-06-28 |
| JP7129973B2 (ja) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17071545A (es) | Inhibidores de bromodominio | |
| CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| CR20190242A (es) | Formas cristalinas de inhibidor de magl | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| CL2019001337A1 (es) | Formulaciones farmacéuticas. | |
| AR114780A1 (es) | Formulaciones estables de inmunoconjugado anti-cd79b | |
| CL2017002214A1 (es) | Formulación de combinación de tesofensina y betabloqueante | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| CL2018001590A1 (es) | Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| CL2017000178A1 (es) | Compuestos para usar en el tratamiento antihelmíntico | |
| CL2018000391A1 (es) | Combinaciones farmacéuticas y su uso | |
| CL2018001157A1 (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. | |
| ECSP18000689A (es) | Composiciones farmacéuticas sólidas para el tratamiento del vhc | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CU20190002A7 (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1 para el tratamiento del cáncer y composiciones farmacéuticas que los comprenden | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
| CL2018003013A1 (es) | Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |